| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0014-2999(96)00903-X |
| P698 | PubMed publication ID | 9059862 |
| P2093 | author name string | Bähr M | |
| Eckel J | |||
| Kolter T | |||
| Seipke G | |||
| P2860 | cites work | Metabolic effects of monomeric insulin analogues of different receptor affinity | Q68110764 |
| Equivalent in vivo biological activity of insulin analogues and human insulin despite different in vitro potencies | Q68533437 | ||
| Superactive insulins | Q68644623 | ||
| [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin | Q72787246 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Muscle cell differentiation is associated with increased insulin receptor biosynthesis and messenger RNA levels | Q34564310 | ||
| NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue | Q35714943 | ||
| The ligand specificities of the insulin receptor and the insulin-like growth factor I receptor reside in different regions of a common binding site | Q37514351 | ||
| Insulin and atheroma. 20-yr perspective | Q37934803 | ||
| Receptor-binding region of insulin | Q39975406 | ||
| Improving insulin therapy: achievements and challenges | Q40500352 | ||
| New directions in drug development: mixtures, analogues, and modeling | Q40810358 | ||
| In vitro and in vivo potency of insulin analogues designed for clinical use. | Q41659434 | ||
| Insulin action on the glucose transport system in isolated cardiocytes from adult rat | Q42062564 | ||
| Contraction-induced translocation of the glucose transporter Glut4 in isolated ventricular cardiomyocytes | Q42457619 | ||
| G-protein-mediated regulation of the insulin-responsive glucose transporter in isolated cardiac myocytes | Q42480901 | ||
| Insulin action on cardiac glucose transport: studies on the role of protein kinase C. | Q42489178 | ||
| Properties of a clonal muscle cell line from rat heart | Q42803058 | ||
| In vitro activity of biosynthetic human diarginylinsulin | Q43484424 | ||
| Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients. | Q44620739 | ||
| Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities | Q44899107 | ||
| Receptor Binding and Tyrosine Kinase Activation by Insulin Analogues With Extreme Affinities Studied in Human Hepatoma HepG2 Cells | Q53737019 | ||
| Insulin dependence of murine lymphoid T-cell leukemia | Q53849843 | ||
| Monomeric insulins obtained by protein engineering and their medical implications | Q59060531 | ||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 259-265 | |
| P577 | publication date | 1997-02-01 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells | |
| P478 | volume | 320 |
| Q55162068 | A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus. |
| Q34906412 | An overview of insulin glargine |
| Q36417426 | Basal insulin treatment in type 2 diabetes |
| Q37890774 | Basal insulin: physiology, pharmacology, and clinical implications |
| Q42707170 | Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel |
| Q37827161 | Controversies in the use of insulin analogues |
| Q38255407 | Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years |
| Q36976992 | Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected]. |
| Q38808885 | Effect of insulin analogues on phosphatidyl inositol-3 kinase/Akt signalling in INS-1 rat pancreatic derived β-cells |
| Q53389588 | Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. |
| Q37503141 | Growth effects of insulin and insulin analogues |
| Q40717341 | Human liver-derived cells stably modified for regulated proinsulin secretion function as bioimplants in vivo. |
| Q44027980 | Insulin Glargine and Cancer Risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy |
| Q35971416 | Insulin analogs and cancer |
| Q35164710 | Insulin analogues and other developments in insulin therapy for diabetes |
| Q54677795 | Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. |
| Q39895082 | Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells |
| Q47614726 | Insulin aspart: a novel rapid-acting human insulin analogue |
| Q34507672 | Insulin glargine |
| Q73578513 | Insulin glargine |
| Q36521871 | Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus |
| Q36964626 | Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes |
| Q34366858 | Insulin glargine and risk of cancer: a meta-analysis |
| Q36012923 | Insulin glargine in the treatment of type 1 and type 2 diabetes |
| Q34648626 | Insulin glargine: a new basal insulin |
| Q35886868 | Insulin glargine: a reevaluation of rodent carcinogenicity findings |
| Q34093019 | Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus |
| Q35177665 | Insulin glargine: a systematic review of a long-acting insulin analogue |
| Q35194343 | Insulin glargine: an updated review of its use in the management of diabetes mellitus |
| Q51514519 | Insulin glargine: the first clinically useful extended-acting insulin in half a century? |
| Q34515529 | Insulin glargine: the first clinically useful extended-action insulin analogue |
| Q73531395 | Insulin therapy in type 2 diabetes |
| Q35807316 | Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue |
| Q34365284 | Insulins today and beyond |
| Q40846310 | Intensive treatment of type 1 diabetes |
| Q36956237 | Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer |
| Q36616563 | Novel insulin analogues and its mitogenic potential |
| Q37296843 | Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study |
| Q33959945 | Synchronization in G0/G1 enhances the mitogenic response of cells overexpressing the human insulin receptor A isoform to insulin |
| Q37806130 | The IGF system. |
| Q90290375 | The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling |
| Q26991486 | The metabolic and mitogenic properties of basal insulin analogues |
Search more.